• +1 513 549 5911 (U.S.)
  • +44 203 318 2846 (U.K.)

30 mins free consultation for each report        Upto 50% Discounts for Highest selling reports

Biosimilar Market

Biosimilar Market, by types (Insulin, human growth hormone, erythropoietin, monoclonal antibodies, interferon, granulocyte-colony stimulating factor), manufacturing type (contract manufacturing and in-house manufacturing), and disease type (blood disorder, autoimmune diseases, oncology, growth hormone deficiency, infectious diseases) forecast till 2025

Market Scenario
Biosimilar drugs are copy drugs similar to the biological drugs that have been already authorized, hence similar but not identical. Biosimilar can be manufactured if the patent of the original product is expired and original innovator officially approved for the development of drugs. It includes medicine derived from biological sources such as bacterium, yeast or blood. Biological medicine is very expensive as the manufacturing process is very complex and requires a huge investment. They are different in structure but have the same mode of action as of original product. In Europe, since 2006, the European medicine agency allowed the commercialization of biosimilar drugs while FDA started it in 2015.

The higher cost of biological medicines, increasing prevalence of chronic diseases, and government initiatives to approve commercialization of biosimilars drives the growth of the market. As per the Forbes projection in near future, around 20% of GDP will be spent on healthcare. Companies producing biosimilar drugs have a profit margin of around 30% and are cost effective. Abbvie’s Humira (adalimumab) is one of the products having the highest sale in 2016 & 2017 and contribute higher share in revenue, which is now available in biosimilar as Cyltezo of Boehringer Ingelheim’s & Amjevita of Amgem’s.

Growing market share of biological drugs in overall pharmaceutical medicines consumption creates an opportunity for biosimilar drugs market. Lack of FDA guidelines, fewer pharmacopeia monographs, huge investment required in setting up biosimilar manufacturing plant, complex process of manufacturing, and lack of economy of scale in production due to low demand can restrain the growth of the market.

Factors influencing the growth of the biosimilar market:
Rising aging population, growing use of biological products to treat a chronic condition, and dependency of health decision on cost supports the market to grow exponentially. Rising prescription of biosimilar drugs by doctors expand the market. According to the Forbes, biosimilars have made it possible to lower the prices of biological drugs by 30% in European Union. Increasing number of firms losing patent protection, government support to use biosimilars, and manufacturer strategy to team up with drug delivery devices companies are boosting the market growth.

Regional Analysis:
Europe is expected to hold the major share in the market, owing to the early commercialization of biosimilar medicines, large product portfolio in biosimilar, liberal government guidelines, and developed healthcare infrastructure. During the last few years, there is a significant increase in the prevalence of different chronic disease in Europe, which has increased the demand for better treatment. North America is expecting a sound growth in near future due to newly formed yielding regulation by FDA to approve biosimilars, growing demand for biological drugs, and higher penetration of players of the market. Presence of huge diabetic population in Americas will drive the market in America. According to the WHO, in 2015, 30.1 million people in America were suffering from diabetes. Increasing numbers of companies indulged in R&D & manufacturing of biosimilar, rising demand of cost-effective biological medicines, and growing awareness of these alternatives to branded drugs stimulate the growth of the market in Asia-Pacific. According to the WHO, over 55% of total global diabetes population is present in Asia-Pacific. The Middle East & Africa hold the least share, owing to the limited development in the healthcare sector and the presence of poor economies in Africa region. The Middle East holds the major share in LAMEA biosimilar market due to the presence of well-developed economies, high health spending, and well-developed healthcare infrastructure.

Major players profiled in this market are:
• Sandoz 
• Teva Pharmaceuticals 
• Amgen 
• Biocon  
• Dr. Reddy’s Laboratories 
• Celltrion  
• samsung Biologics 
• Hospira 
• Mylan 
• STADA Arzneimittel  

Recent Developments:
In January 2018, Biocon, one of the leader players in biosimilar market, signed a deal with Sandoz, the arm company of Novartis to jointly invest, develop, and market new product portfolio of biosimilar in cancer and immunology for global market.

In March 2016, Dr Reddy's and TR-Pharm entered into a strategic collaboration agreement for production and commercialisation of biosimilar drugs in Turkey.

In December 2017, First biosimilar called trastuzumab used for breast and stomach cancer was developed by Mylan-Biocon and approved by FDA in US. 

Strategic agreement between pharmaceutical companies to develop biosimilar drugs is widely adopted strategy use by players in this market.

By Types:
• Insulin
• Human growth hormone
• Erythropoietin
• Monoclonal antibodies
• Interferon
• Granulocyte-Colony Stimulating Factor
• Others

By Type of Manufacturing:
• Contract Manufacturing
• In-house Manufacturing

By Diseases type:
• Blood Disorder
• Autoimmune Diseases
• Oncology
• Growth Hormone Deficiency
• Infectious Diseases
• Others

By Region:
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Australia
o Rest of Asia-Pacific
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA



Related Reports


Global Hepatocellular Carcinoma Drugs Market Report, History and Forecast 2014-2025, Breakdown Data by Manufacturers, Key Regions, Types and Application

Summary HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the sec ...read more


Global Hepatitis Drugs Market Report, History and Forecast 2014-2025, Breakdown Data by Manufacturers, Key Regions, Types and Application

Summary Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system ...read more


Global Hepatitis B and C Diagnostics Market Report, History and Forecast 2014-2025, Breakdown Data by Companies, Key Regions, Types and Application

Summary Hepatitis B diagnostic tests include HBV serologic tests, molecular deoxyribonucleic acid (DNA) tests, histology tests, and laboratory tests. HBV serologic tests involve the measurement of an ...read more


Global Hepatic Encephalopathy (HE) Therapeutics Market Report, History and Forecast 2014-2025, Breakdown Data by Manufacturers, Key Regions, Types and Application

Summary HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood. The availability of patient-focused programs to assist d ...read more


Global Hemophilia Drugs Market Report, History and Forecast 2014-2025, Breakdown Data by Manufacturers, Key Regions, Types and Application

Summary The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more pro ...read more

Choose License Type

Single User - This is a single user license, allowing one specific user access to the product.

Multi User - This is a 1-5 user licence, allowing up to five users have access to the product.

Enterprise User - This is an enterprise license, allowing all employees within your organisation access to the product. The report will be emailed to you.

Cards For Payment
Trusted Badge SSL Certified Premium Quality

Why Choose Us

  • Lowest Price Guarantee
  • We offer the lowest prices for the listed reports
  • Data Security
  • Your data is safe and secure
  • Vast Report Database
  • We have more than 2 Million reports in our database
  • Client Focused
  • Personalized updates and 24*7 support
  • Trusted Source and Quality
  • We only work with reputable partners providing high quality research and support
  • Market Segmentation
  • We provide alternative views of the market to help you identify where the real opportunities lie
  • Bulk Discounts
  • We offer great discounts on purchase of multiple reports

How To Reach Us

Reach out to our most senior Sales Professional- Jay Matthews
   +1 513 549 5911 (US)
          +44 203 318 2846 (UK)

Our Clients

Intel Samsung 3M BCG LEK Consulting McKinsey Thyssenkrupp Mogensen BASF IQVIA Hella Oracle Accenture Saint Gobain


Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed.
-VP of a Automotive division in Germany

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements
-Product Manager at US based Manufacturer

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process
--Marketing Manager at a pharma company in Belgium

Enquire Before Buying

Need to ask a quick question before buying? Please fill out this short form:

Our Features

Wide Network of Publishers

Wide Network of Publishers

Access to over 1M+ market research reports

Trusted by the Best

Trusted by the Best

50+ Clients in Fortune 500

Competitive Pricing

Competitive Pricing

Our regular promotional offers and discounts make us the most economic seller of market reports

Safe and Secure

Safe and Secure

Your payment details are protected by us.